Vol. 285, Issue 3, 1104-1112, June 1998

Metabolism and Transport of the Macrolide Immunosuppressant Sirolimus in the Small Intestine¹

Alfonso Lampen, Yuanchao Zhang, Ina Hackbarth, Leslie Z. Benet, Karl-Fr. Sewing and Uwe Christians

Zentrumsabteilung für Lebensmitteltoxikologie, Tierärztliche Hochschule Hannover, Hannover, Germany (A.L.); Department of Biopharmaceutical Sciences, School of Pharmacy, University of California at San Francisco, San Francisco, California (Y.Z., L.Z.B., U.C.); Institut für Allgemeine Pharmakologie, Medizinische Hochschule Hannover, Hannover, Germany (I.H., K.-Fr.S.); and Department of Cardiothoracic Surgery, Stanford University, Stanford, California (U.C.)

Small intestinal metabolism and transport of sirolimus, a macrolide immunosuppressant with a low and highly variable oral bioavailability, were investigated using small intestinal microsomes and intestinal mucosa in the Ussing chamber. After incubation of sirolimus with human and pig small intestinal microsomes, five metabolites were detected using high performance liquid chromatography/electrospray-mass spectrometry: hydroxy, dihydroxy, trihydroxy, desmethyl and didesmethyl sirolimus. The same metabolites were generated by human liver microsomes and pig small intestinal mucosa in the Ussing chamber. Anti-CYP3A antibodies, as well as the specific CYP3A inhibitors troleandomycin and erythromycin, inhibited small intestinal metabolism of sirolimus, confirming that, as in the liver, CYP3A enzymes are responsible for sirolimus metabolism in the small intestine. Of 32 drugs tested, only known CYP3A substrates inhibited sirolimus intestinal metabolism with inhibitor constants (K_i) equal to those in human liver microsomes. The formation of hydroxy sirolimus by small intestinal microsomes isolated from 14 different patients ranged from 28 to 220 pmol·min¹·mg¹ microsomal protein. In the Ussing chamber, >99% of the sirolimus metabolites reentered the mucosa chamber against a sirolimus gradient, indicating active countertransport. Intestinal drug metabolism and countertransport into the gut lumen, drug interactions with CYP3A substrates and inhibitors in the small intestine and an 8-fold interindividual variability of the intestinal metabolite formation rate significantly contribute to the low and highly variable bioavailability of sirolimus.